34019-61-9

Basic information

• Product Name: 1-(4-chlorophenyl)-2H-pyridazine-3,6-dione
• Synonyms: 1-(4-chlorophenyl)-2H-pyridazine-3,6-dione
• CAS NO: 34019-61-9
• Molecular Formula: C₁₀H₇ClN₂O₂
• Molecular Weight: 0
• Mol File: 34019-61-9.mol
• Article Data: 2

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.427g/cm³
• Refractive Index: 1.616
• CAS DataBase Reference: 1-(4-chlorophenyl)-2H-pyridazine-3,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-chlorophenyl)-2H-pyridazine-3,6-dione(34019-61-9)
• EPA Substance Registry System: 1-(4-chlorophenyl)-2H-pyridazine-3,6-dione(34019-61-9)

Safety Data

• Hazardous Substances Data: 34019-61-9(Hazardous Substances Data)

Usage

General Description

1-(4-chlorophenyl)-2H-pyridazine-3,6-dione is a chemical compound with the molecular formula C10H5ClN2O2. It is a pyridazine derivative with a 4-chlorophenyl group attached to the pyridazine ring. 1-(4-chlorophenyl)-2H-pyridazine-3,6-dione is a potential pharmaceutical intermediate with applications in the synthesis of various drugs and biologically active compounds. It may also have uses in the field of organic and medicinal chemistry for the development of new therapeutic agents. The chemical structure and properties of 1-(4-chlorophenyl)-2H-pyridazine-3,6-dione make it an interesting and important molecule for further research and exploration in the field of pharmaceutical chemistry.

InChI:InChI=1/C10H7ClN2O2/c11-7-1-3-8(4-2-7)13-10(15)6-5-9(14)12-13/h1-6H,(H,12,14)

Upstream product

• 110-16-7 maleic acid 
• 1073-69-4 N-4-chlorophenylhydrazine 
• 108-31-6 maleic anhydride 
• 1073-70-7 4-chlorophenylhydrazine hydrochloride 

Relevant articles and documents

Synthesis and Biological Evaluation of Novel σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones

By use of the 6-hydroxypyridazinone framework, a new series of potent σ1 receptor ligands associated with pharmacological antineuropathic pain activity was synthesized and is described in this article. In vitro receptor binding studies revealed high σ1 receptor affinity (Ki σ1 = 1.4 nM) and excellent selectivity over not only σ2 receptor (1366-fold) but also other CNS targets (adrenergic, μ-opioid, sertonerigic receptors, etc.) for 2-(3,4-dichlorophenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2H)-one (compound 54). Compound 54 exhibited dose-dependent antiallodynic properties in mouse formalin model and rats chronic constriction injury (CCI) model of neuropathic pain. In addition, functional activity of compound 54 was evaluated using phenytoin and indicated that the compound was a σ1 receptor antagonist. Moreover, no motor impairments were found in rotarod tests at antiallodynic doses and no sedative side effect was evident in locomotor activity tests. Last but not least, good safety and favorable pharmacokinetic properties were also noted. These profiles suggest that compound 54 may be a member of a novel class of candidate drugs for treatment of neuropathic pain.